Cystic Fibrosis Research Limited

Grants to research

Cystic Fibrosis Research Limited was established by Cystic Fibrosis Queensland to administer and grow a nest egg of bequests and donations to further the search for a cure to CF and to assist in palliative care research.

CFR is independently run by a board of volunteers with business expertise. Its outlays are minimal, being confined to unavoidable statutory fees.

CFR's cumulative investment in research now exceeds $1,087,672. Most has been as seed funding in original research, many projects having started with our support and graduated to major funding from organizations such as National Health and Medical Research Council and international agencies.

CFRL has held off allocating funds to research projects over recent years which has allowed the portfolio to grow and the ability to fund larger projects which are currently being assessed. An outline of the supported projects over the years if outlined as follows;

2022-2023 (Calendar YTD)

$48,074 Research Grant Funding – UQ/Price Charles Hospital - New pathways to treat intractable lung infection in lung transplant recipients with CF - Amy Pham

Additional $40,000 to Cystic Fibrosis Australia Innovation Grant on improving detection and assessment of lung disease in young children with cystic fibrosis. Dr Tamara Blake.

2021-2022 (2022 calendar year)

$40,000 (partial payment, with commitment to additional $40,000 pending) to Cystic Fibrosis Australia Innovation Grant on improving detection and assessment of lung disease in young children with cystic fibrosis. Dr Tamara Blake.

2020-2021 (2021 calendar year)

$15,000 ACFFRT Post Graduate Studentship Grant - funding made up of three yearly $5,000 instalments on the provision of a requirement for six monthly reporting. Rebecca Keating - *"Investigation of factors influencing glucose control in cystic fibrosis".*

$80,000 for an innovation grant finalist. Dr. Abdullah A Tarique, Prof. Peter D Sly, Dr. Emmanuelle Fantin, Prof. Clair Wainwright, Prof. Scott C. Bell *'Enhancing the innate ability of CF macrophages to kill and clear MABS background'* at the University of Queensland. RNA therapy modifies or provides ribonucleic acid to patients' cells. The research looked at whether RNA based therapeutic treatments for other disorders can establish drug delivery techniques that will effectively translate BGas (gene manipulation) suppressing compounds into an innovative cystic fibrosis therapy.

2017-2018 (2018 calendar year)

$70,000 to a project titled *'RNA Therapeutics: Novel Paradigm in Mutuation Independent CF Therapy' (BGas Gene Manipulation).*

$42,000 to a University of Queensland Project for *'CyFit Telehealth Project: web-based data management and clinical support system'*

2016-2017 (2017 calendar year)

$30,000 to University of Queensland, Trevor Russell, for the project *'CyFiT Telehealth: web-based data management and clinical support system'.*

2011-2012

$80,619 to a project based at Queensland Institute of Medical Research. Includes Dr DW. Reid, A/Prof. SC. Bell, A/Prof. MA Schembri, Prof. IL. Lamont. *Targeting the Achilles Heel of P.aeruginosa biofilms.*

2010-2011

$20,000 to the University of NSW for *"The gut/lung axis: discovering and understanding the gut microbiota in CF".*

2009-2010
$68,950 to a project based at Queensland Children's Medical Research Institute. Includes Dr D.M.Wiley, Mr T.J.Kidd, Ms S.Anuj, A/Prof C.T.Sloots, A/Prof S.C.Bell, A/Prof M.D.Nissen, Prof K.Grimwood, A/Prof C.E.Wainwright and Dr R.Ware. *Development of a novel assay for the detection of clonal P.aeruginosa in persons with CF.*

2008-2009
$83,840 to a team led by A/Prof Scott Bell (director of CF, Dept of Thoracic Medicine at Prince Charles Hospital (Brisbane) *"Multilocus sequence typing of Pseudomonas aeruginosa from different niches"* The work will be carried out at the Queensland Paediatric Infectious Disease Laboratory, Royal Children's Hospital.

2007-2008
$84,340 to a University of Western Australia project entitled *"Validating 8- oxodG as a biomarker of oxidative stress in children with CF."*
The team is led by Prof Peter Sly with other main players A/Prof Anthony Kettle (Department of Pathology, Uni of Otago), Dr Marcus Cooke (Department of Cancer Studies and Department of Genetics, Uni of Leicester) and Prof Jonathan Grigg (Prof of Paediatric and Environmental Medicine, Queen Mary Uni, London).

2006-2007
$54,101 to an international joint venture involving Australia and Canada, a study entitled *"Evaluation of a decision aid for adult CF patients considering lung transplantation".* The administering institution is Royal Prince Alfred Hospital, Sydney in cooperation with Prince Charles Hospital, Brisbane.

Our funding for the Australian part of the study followed funding of the Canadian portion by Ontario Thoracic Society and The Physicians' Services Incorporated Foundation and reflects our wish to encourage international sharing of research opportunity and outcome.

2005-2006
$59,250 for a project entitled *"Improving self management in adolescents and adults with CF".* The study is led by Dr David Reid and A/Prof Claire Wainwright. It involves effort at both Royal Childrens' Hospital, Brisbane, and Royal Hobart Hospital. If successful, this could lead to rapid take-up of the proven techniques across the world.

2003-2004
During this two-year period CFRL completed its largest contribution ever to a single research project, a sum of $171,000 over two years. The work was conducted at Royal Children's Hospital Melbourne and Murdoch Institute. It was entitled "Computed tomographic airway morphometry as an assessment tool." The next phase has attracted larger funding from Australia and the United States.

It appears to be another successful outcome of our focus on start-up research. Our finances are limited and big ticket advanced research projects are better handled by National Health and Medical Research Council and other sponsors.

2001-2002
$30,000 to project entitled *"Synergy testing of multi-drug resistant bacteria in CF"* Based at the University of Sydney it involved A/Profs C. Harbour, P. Bye and R. Benn and Dr B. Rose.

2000-2001
$30,000 to *"Mechanisms for inhibition of amiloride-sensitive Na+ absorption in the*

airways" led by Dr Karl Kunzlemann, senior lecturer Department of Physiology and Pharmacology, University of Queensland.

1999-2000
$49,956 to *"Evaluation of hepatic fibrogenesis in CF liver disease"* – Royal Children's Hospital, Brisbane.
$48,616 to teams at Royal Children's and Prince Charles Hospitals (Brisbane) *"Osteoporosis in children and adults with CF"*

1998-1999
$30,000 to *"The role of protease activated receptors in CF lung pathology"* – Drs G. Stewart and A. McMillan, University of Western Australia.

Earlier Years

"Long term administration of hypertonic saline in CF" – A/Prof P.Bye and C.Ellis, Drs P.Cooper and S.Parsons at Royal Prince Alfred Hospital, Sydney.

"The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with CF" – Dr Andrew Cotterill, Mater Children's Hospital, Brisbane.

"Delivery of deoxyribonuclease (Dnase) to infants and children with CF using different nebuliser systems" – Dr S.Devadason and A/Prof P. Le Souef at Princess Margaret Hospital for Children, Perth.

"Gene therapy for CF airway disease: development and evaluation of a new vestor" - Drs D.Anson and D.Parsons at Women's and Children's Hospital, Adelaide.

"Effect of education on home physiotherapy for children with CF" – Ms J. Downs, Ms S.Giles and Dr S.Jenkins at Princess Margaret Hospital for Children, Perth.

"Carer respite and development of support groups plus needs of adults with CF" – Ms Orma Ringberg, Cystic Fibrosis Association of Qld.

"Respiratory infection, inflammation and pulmonary function in CF infants" – Dr Claire Wainwright at Royal Children's Hospital, Brisbane.

Others include: genetic research (Prof Brandon Wainwright) at the Institute for Molecular Bioscience, University of Queensland; *Research into cytokines* (Dr Jo Walter) Brisbane*; Diets* (Liz Powell) Brisbane; plus projects by Brisbane doctors, Dr Ross Shepherd, Dr Paul Francis and others.